



INTERNATIONAL GENERIC AND  
BIOSIMILAR MEDICINES ASSOCIATION

Info: [info@igbamedicines.org](mailto:info@igbamedicines.org)

## **IGBA's CEO Advisory Committee advances strategic focus on access to medicines**

For immediate release

Geneva, 28 May 2024

Chief Executive Officers of the world's largest generic and biosimilar medicines companies<sup>1</sup> met in Vienna on 15 May 2024 to provide strategic advice to the International Generic and Biosimilar Medicines Association (IGBA). The generics and biosimilars sector, which supplies 70 to 90% of prescribed medicines around the world, is united in seeking to enable innovation and competition to improve patients' access to quality-assured, safe and cost-effective medicines.

The [IGBA CEO Advisory Committee](#) offered strong support for IGBA's advancement of global efforts to address barriers to medicine access, including:

- Promoting regulatory cooperation, convergence and harmonization of standards for the approval of generic and biosimilar medicines.
- Promoting the widest possible access to safe, effective and quality-assured medicines for patients globally.
- Promoting balanced pharmaceutical intellectual property regimes that foster innovation and allow timely launch of generic and biosimilar medicines, while supporting fair competition and preventing risks of IP abuses and evergreening globally.
- Fostering the sustainability of medicine manufacturers in the interests of healthcare systems and patients.

[Vinita Gupta](#), Chief Executive Officer of Lupin Limited, and Chair of IGBA's CEO Advisory Committee, noted *"We are delighted to see the progress IGBA is making with the support of its members in advancing our key priorities to ensure access to affordable medicines."*

[Adrian van den Hoven](#), Chair of the IGBA, added *"The global industry CEOs bring leadership and drive to the IGBA mission of improving access to medicines for patients all around the world. With their commitment, the IGBA will deliver concrete projects to remove barriers to medicines access, including: a lack of regulatory alignment among countries and regions; the proliferation of patent thickets and; the absence of sustainable market policies to encourage rational use of generic and biosimilar*

---

<sup>1</sup> The IGBA CEO Advisory Committee includes 15 CEOs from the largest companies in the sector from across the globe  
<https://www.igbamedicines.org/about-us/ceo-advisory-committee>



*medicines. The voice of the generic and biosimilar medicines industry is going to get a lot louder about barriers to medicines access.”*

**About us:** The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: [www.igbamedicines.org](http://www.igbamedicines.org).